Prolonged overall survival in a child with multimetastatic retinoblastoma treated with anti-GD2 monoclonal antibody dinutuximab beta: a case report.

Saved in:
Bibliographic Details
Title: Prolonged overall survival in a child with multimetastatic retinoblastoma treated with anti-GD2 monoclonal antibody dinutuximab beta: a case report.
Authors: Di Ruscio V; Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy., Carboni A; Neuroradiology Unit, 'Bambino Gesù' Children's Hospital Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy., Del Baldo G; Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy., De Pasquale MD; Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy., Valente P; Ophthalmology Unit, Bambino Gesù Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Children's Hospital, Rome, Italy., Di Giannatale A; Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy., Serra A; Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy., De Vito R; Pathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy., Mastronuzzi A; Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy., Quintarelli C; Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy., De Angelis B; Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy., Milano GM; Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy., Russo I; Department of Onco-Hematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Scientific Institute for Research, Hospitalization and Healthcare Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Source: Frontiers in oncology [Front Oncol] 2025 Oct 17; Vol. 15, pp. 1665968. Date of Electronic Publication: 2025 Oct 17 (Print Publication: 2025).
Publication Type: Case Reports; Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2234-943X
DOI:10.3389/fonc.2025.1665968